|
|
 | | | |
- close
- close
- close
- close
United Therapeutics (UTHR) |
Market Intelligence Center
May 20
Comment
United Therapeutics (NASDAQ: UTHR) closed Friday's trading session at $69.17. In the past year, the stock has hit a 52-week low of $41.55 and 52-week high of $69.21. United Therapeutics (UTHR) stock has been showing support around $67.20 and...
Market Intelligence Center
May 1
Comment
United Therapeutics (NASDAQ: UTHR) closed Tuesday's trading session at $66.78. In the past year, the stock has hit a 52-week low of $41.55 and 52-week high of $68.25. United Therapeutics (UTHR) stock has been showing support around $63.40 and...
StreetInsider.com
Apr 25
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/United+Therapeutics+%28UTHR%29+Posts+Q1+EPS+of+%241.24/8277927.html for the full story.
Market Intelligence Center
Apr 25
Comment
United Therapeutics (NASDAQ: UTHR) closed Wednesday's trading session at $63.22. In the past year, the stock has hit a 52-week low of $41.42 and 52-week high of $64.00. United Therapeutics (UTHR) stock has been showing support around $60.09 and...
Stock Blog Hub
Apr 21
Comment
United Therapeutics Corporation (UTHR) recently gained approval for the commencement of a phase I study in Australia using Pluristem Therapeutics Inc.’s (PSTI) PLacental eXpanded (PLX-PAD) cells. The study will be conducted in patients suffering...
Market Intelligence Center
Apr 19
Comment
United Therapeutics (NASDAQ: UTHR) closed Thursday's trading session at $59.67. In the past year, the stock has hit a 52-week low of $40.65 and 52-week high of $63.11. United Therapeutics (UTHR) stock has been showing support around $58.52 and...
Benzinga
Apr 11
Comment
Pluristem Therapeutics (NASDSQ: PSTI) announced today that following favorable preclinical studies, United Therapeutics Corporation received approval to perform a human Phase I study in Australia using Pluristem's PLacental eXpanded (PLX-PAD)...
Market Intelligence Center
Mar 27
Comment
United Therapeutics (NASDAQ: UTHR) closed Tuesday's trading session at $60.39. In the past year, the stock has hit a 52-week low of $40.34 and 52-week high of $63.11. United Therapeutics (UTHR) stock has been showing support around $59.20 and...
Benzinga
Mar 25
Comment
Idenix Pharmaceuticals (NASDAQ: IDIX) shares fell 8.70% to $4.20 in the pre-market trading after the company lost its first phase of a patent dispute with Gilead Sciences (NASDAQ: GILD).
United Therapeutics (NASDAQ: UTHR) dipped 6.87% to $56.76...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS|
Error creating thumbnail: convert: unable to open image `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png': No such file or directory @ blob.c/OpenBlob/2480. convert: unable to open file `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png' @ png.c/ReadPNGImage/2889. convert: missing an image filename `/home/wikinvest/src_live_2/mediawiki/images/thumb/9/98/New_stock.png/35px-New_stock.png' @ convert.c/ConvertImageCommand/2800. |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
